Clinical Trial Update: Celecoxib in Treating Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer [NA]

View source ↗

Summary

A completed clinical trial evaluated celecoxib for treating patients with stage I to IIIA non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CELEBREX (Celecoxib)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Lung Cancer | NA | Status: COMPLETED